Stock comparison
Merck & Co., Inc. is 14.6x more valuable than Royalty Pharma plc by market capitalization ($308.78 B vs $21.16 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRK is larger
Merck & Co., Inc. is 14.6x more valuable than Royalty Pharma plc by market capitalization ($308.78 B vs $21.16 B).
Market value leader
MRK
Merck & Co., Inc. is 14.6x more valuable than Royalty Pharma plc by market capitalization ($308.78 B vs $21.16 B).
Revenue leader
MRK
RPRX: $2.38B vs MRK: $65.01B.
Profit leader
MRK
RPRX: $770.95M vs MRK: $18.25B.
Margin leader
RPRX
RPRX: 32.4% vs MRK: 28.1% net margin.
| Metric | RPRX | MRK |
|---|---|---|
| Market cap | $21.16 B | $308.78 B |
| US-listed rank | #608 | #45 |
| Revenue (latest FY) | $2.38B | $65.01B |
| Net income (latest FY) | $770.95M | $18.25B |
| Net margin | 32.4% | 28.1% |
| P/E (trailing FY) | 27.4x | 16.9x |
| SEC filings | 588 | 998 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Merck & Co., Inc. is 14.6x more valuable than Royalty Pharma plc by market capitalization ($308.78 B vs $21.16 B).
In their latest fiscal years, Royalty Pharma plc reported $2.38B in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Royalty Pharma plc and Merck & Co., Inc., or browse the full rankings.